Zobrazeno 1 - 10
of 10
pro vyhledávání: '"ANDREW BETT"'
Autor:
Brian K. Meyer, Debbie Nahas, Myunggi An, Andrew Danziger, Jeffrey Smith, Manish Patel, Shu-An Lin, Alexa Gleason, Kara Cox, Robert Capen, John Howe, Andrew Bett
Publikováno v:
Vaccine: X, Vol 16, Iss , Pp 100420- (2024)
Described here is the evaluation of a luciferase (luc) and respiratory syncytial virus (RSV) messenger RNA / lipid nanoparticle (mRNA/LNP) vaccine using a Needle-free Injection System, Tropis®, from PharmaJet® (Golden, Colorado USA). Needle-free je
Externí odkaz:
https://doaj.org/article/36511318351348fe92dd3417c22f13ce
Autor:
Susan B. Manoff, Michele Sausser, Amy Falk Russell, Jason Martin, David Radley, Donna Hyatt, Christine C. Roberts, Jason Lickliter, Janakan Krishnarajah, Andrew Bett, Sheri Dubey, Tyler Finn, Beth-Ann Coller
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 9, Pp 2195-2204 (2019)
There is an unmet medical need for vaccines to prevent dengue. V180 is an investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) for all 4 serotypes. Three dosage levels of the tetravalent DEN-80E an
Externí odkaz:
https://doaj.org/article/e4be8a3f1f7443309a7d49c43205d80c
Autor:
Aimin Tang, Daniel C. Freed, Fengsheng Li, Steve Meschino, Michael Prokop, Andrew Bett, Danilo Casimiro, Dai Wang, Tong-Ming Fu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 12, Pp 2763-2771 (2017)
T cell immunity is critical in controlling human cytomegalovirus (HCMV) infection in transplant recipients, and T cells targeting viral immediate early proteins such as IE1, IE2 and pp65 have been speculated to be more effective against reactivation.
Externí odkaz:
https://doaj.org/article/dd698df3143a40e3828f2012477d580b
Autor:
Hualin Li, Cheryl Callahan, Michael Citron, Zhiyun Wen, Sinoeun Touch, Morgan A Monslow, Kara S Cox, Daniel J DiStefano, Kalpit A Vora, Andrew Bett, Amy Espeseth
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0187642 (2017)
Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in young children and older adults throughout the world. Prevention of severe RSV disease through active immunization is optimal but no RSV vaccine has be
Externí odkaz:
https://doaj.org/article/e018d3e0e3ee41dbb4b9118e502bda6f
Autor:
Zhifeng Chen, Lan Zhang, Aimin Tang, Cheryl Callahan, Pavlo Pristatsky, Ryan Swoyer, Pedro Cejas, Debbie Nahas, Jennifer Galli, Scott Cosmi, Daniel DiStefano, Van M Hoang, Andrew Bett, Danilo Casimiro, Kalpit A Vora
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0156798 (2016)
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants, the elderly and in immunosuppressed populations. The vast majority of neutralizing antibodies isolated from human subjects target the RSV fusion (F)
Externí odkaz:
https://doaj.org/article/73155741d0404b628aaa41985e4d1d0a
Autor:
Antonia R Bass, Sonya Kimball, Anjelica Jenkins, Aimee Burton, Katherine Trostle, Halea Corcoran, Meredith Allen, Catherine Gallagher, Jacque Harms, Andrew Bett, Nicole Sullivan
Publikováno v:
The Journal of Immunology. 208:50.01-50.01
Adjuvants are crucial components of subunit vaccines, as they help induce immune responses to poorly immunogenic antigens. Merck has developed a variety of lipid nanoparticles (LNPs) that contain different cationic lipids, a critical component that i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23ff61d523236ca5fc0163cb34e60e30
https://doi.org/10.4049/jimmunol.208.supp.50.01
https://doi.org/10.4049/jimmunol.208.supp.50.01
Autor:
Gokul Swaminathan, Shu-An Lin, ManishKumar Patel, Katie DiFelice, Jeffrey Smith, Marian Gindy, Ashley Mahne, Daniel Cua, Danilo Casimiro, Amy Espeseth, Andrew Bett
Publikováno v:
The Journal of Immunology. 198:79.2-79.2
Emerging evidence suggests that bioengineered nanoparticles can be used as immunomodulatory agents. Using murine and non-human primate vaccination models, we have identified novel cationic lipid nanoparticles (LNPs) that significantly enhance antigen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1f6f71e238e788e87f406486ea0e12e
https://doi.org/10.4049/jimmunol.198.supp.79.2
https://doi.org/10.4049/jimmunol.198.supp.79.2
Autor:
Kara S. Cox, I-Ming Wang, Alexey Nefedov, Xiaohua Douglas Zhang, Sheri Dubey, Andrew Bett, Danilio Casimiro, Judith Mandl, Mark B. Feinberg
Publikováno v:
The Journal of Immunology. 196:203.8-203.8
Innate immunity is an evolutionary mechanism which is involved in the initial detection of pathogens and stimulates the first line of host defense. The Toll-like receptor (TLR) family has been the most extensively studied innate immune pathway and it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fa90ebbed39575cea6bf7903a6d0608
https://doi.org/10.4049/jimmunol.196.supp.203.8
https://doi.org/10.4049/jimmunol.196.supp.203.8
Autor:
MARIE E. CSETE, KENNETH E. DRAZAN, MARK VAN BREE, DIANE F. MCINTEE, WILLIAM H. MCBRIDE, ANDREW BETT, FRANK L. GRAHAM, RONALD W. BUSUTTIL, ARNOLD J. BERK, ABRAHAM SHARED
Publikováno v:
Transplantation. 57:1502-1507
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e0f3b05871b7616686aa81cf077d1c6
https://doi.org/10.1097/00007890-199405270-00018
https://doi.org/10.1097/00007890-199405270-00018
Autor:
Matthieu Perreau, Hugh Welles, Olivia Hall, Alexandre Harari, Stephanie Bibert, Ricardo Martin, Thierry Roger, Thierry Calandra, Andrew Bett, Jason Gall, Eric Kremer, Giuseppe Pantaleo
Publikováno v:
The Journal of Immunology. 186:53.27-53.27
Adenovirus serotype 5 (Ad5) phase IIb vaccine trial (STEP) was prematurely stopped due to a lack of efficacy and two-fold higher incidence of HIV infection among Ad5 seropositive vaccine recipients. We have recently demonstrated that Ad5 immune compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea860bf7ccd232d246967c0a0a50d158
https://doi.org/10.4049/jimmunol.186.supp.53.27
https://doi.org/10.4049/jimmunol.186.supp.53.27